Breaking News

Orano Med Breaks Ground on New Manufacturing Site

Lays foundations for Europe's first industrial-scale pharmaceutical facility dedicated to the production of lead-212 based radioligand therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Orano Med (a subsidiary of the Orano Group), a developer of targeted alpha therapies for oncology, has laid the foundation stone for its ATLab (Alpha Therapy Laboratory) in Onnaing (France, 59)—which will be Europe’s first industrial-scale pharmaceutical facility dedicated to the production of lead-212 based radioligand therapies.   The ground-breaking ceremony was attended by Xavier Jouanin, Mayor of Onnaing, Laurent Degallaix, President of Valenciennes Métropole and Mayor of Valencienn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters